59352-5 |
Tapentadol |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Tapentadol [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
0.5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59352-5 |
|
|
|
|
Both |
|
|
|
0 |
Tapentadol Bld-mCnc |
|
|
|
N |
|
Addiction; Blood; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Level; Mass concentration; Nucynta; Palexia; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; Tapal; WB; Whole blood |
2.73 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59353-3 |
Tapentadol |
MCnc |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
Tapentadol [Mass/volume] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
0.5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59353-3 |
|
|
|
|
Both |
|
|
|
0 |
Tapentadol Fld-mCnc |
|
|
|
N |
|
Addiction; B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Fl; Fld; FLU; Fluid; Illicit; Level; Mass concentration; Nucynta; Palexia; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; Tapal |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59354-1 |
Tapentadol |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Tapentadol [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
0.5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59354-1 |
|
|
|
|
Both |
|
|
|
0 |
Tapentadol SerPl-mCnc |
|
|
|
N |
|
Addiction; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Level; Mass concentration; Nucynta; Palexia; Pl; Plasma; Plsm; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tapal |
2.73 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59355-8 |
Tapentadol |
MCnt |
Tiss |
Pt |
Qn |
|
|
ACTIVE |
Tapentadol [Mass/mass] in Tissue |
|
MIN |
DefinitionDescription |
|
|
ng/g |
0.5 ng/g |
|
|
|
|
|
DRUG/TOX |
|
59355-8 |
|
|
|
|
Both |
|
|
|
0 |
Tapentadol Tiss-mCnt |
|
|
|
N |
|
Addiction; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Mass Content; Nucynta; Palexia; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; Tapal; Tissue; Tissue, unspecified |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/g |
|
|
Changed Property from 'MCnc' it fit the current LOINC model. |
0 |
59356-6 |
Desethylvardenafil |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Desethylvardenafil [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59356-6 |
|
|
|
|
Both |
|
|
|
0 |
Desethylvardenafil Bld-mCnc |
|
|
|
N |
|
Blood; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Phosphodiesterase #5 inhibitor; Phosphodiesterase 5 inhibitor; Point in time; QNT; Quan; Quant; Quantitative; Random; Vardenafil metabolite; WB; Whole blood |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59357-4 |
Vardenafil |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Vardenafil [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59357-4 |
|
|
|
|
Both |
|
|
|
0 |
Vardenafil Bld-mCnc |
|
|
|
N |
|
Blood; DRUG/TOXICOLOGY; Drugs; Level; Levitra; Mass concentration; Phosphodiesterase #5 inhibitor; Phosphodiesterase 5 inhibitor; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59358-2 |
Desethylvardenafil |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Desethylvardenafil [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59358-2 |
|
|
|
|
Both |
|
|
|
0 |
Desethylvardenafil SerPl-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Phosphodiesterase #5 inhibitor; Phosphodiesterase 5 inhibitor; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Vardenafil metabolite |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59359-0 |
Vardenafil |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Vardenafil [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59359-0 |
|
|
|
|
Both |
|
|
|
0 |
Vardenafil SerPl-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; Levitra; Mass concentration; Phosphodiesterase #5 inhibitor; Phosphodiesterase 5 inhibitor; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
5936-0 |
Benzoylecgonine |
MCnt |
Hair |
Pt |
Qn |
|
|
ACTIVE |
Benzoylecgonine [Mass/mass] in Hair |
|
MIN |
DefinitionDescription |
|
|
ng/g |
|
|
|
|
|
|
DRUG/TOX |
|
5936-0 |
|
|
|
|
Both |
|
|
|
0 |
BZE Hair-mCnt |
|
|
|
Y |
|
BEC; BEG; Benz; Benzoylec; BZE; Cocaine degradation production; Cocaine metabolite; Crack metabolite; DRUG/TOXICOLOGY; Drugs; Har; Mass content; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.73 |
1.0d |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
59360-8 |
Desethylvardenafil |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Desethylvardenafil [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59360-8 |
|
|
|
|
Both |
|
|
|
0 |
Desethylvardenafil Ur-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Phosphodiesterase #5 inhibitor; Phosphodiesterase 5 inhibitor; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn; Vardenafil metabolite |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59361-6 |
Vardenafil |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Vardenafil [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59361-6 |
|
|
|
|
Both |
|
|
|
0 |
Vardenafil Ur-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; Levitra; Mass concentration; Phosphodiesterase #5 inhibitor; Phosphodiesterase 5 inhibitor; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59362-4 |
Race or ethnicity |
Type |
^Patient |
Pt |
Nom |
OMB.1997 |
|
ACTIVE |
Race or ethnicity OMB.1997 |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
PID-10;PID-22 |
|
|
CLIN |
|
59362-4 |
|
OMB.1997 |
|
|
Both |
|
|
|
0 |
Race or ethnicity OMB.1997 |
|
|
|
N |
|
CLIN; Ethnicity; Nominal; Point in time; Random; Typ |
2.63 |
2.32 |
|
|
|
|
|
|
|
|
|
|
Changed method from 'MDSv3' to 'OMB.1997' since the MDSv3 answer list is the same as OMB's combined race & ethnicity answer list (1997). OMB provides standards that promote uniformity and comparability for data on race and ethnicity throughout the U.S. Federal Government. These standards are widely adopted, including in the EHR Meaningful Use program within the U.S. |
0 |
59363-2 |
Leptospira interrogans serovar Manhao Ab |
Titr |
Ser |
Pt |
SemiQn |
Aggl |
|
ACTIVE |
Leptospira interrogans sv Manhao Ab [Titer] in Serum by Agglutination |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
59363-2 |
|
Aggl |
|
|
Both |
|
|
|
0 |
L inter Manhao Ab Titr Ser Aggl |
|
|
|
N |
|
ABS; Aby; Agg; Agglut; Agglutination; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); ID; Infectious Disease; InfectiousDisease; L inter; L inter Manhao; L interrogans; Leptospirosis; Microbiology; Point in time; Random; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
2.32 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
59364-0 |
Leptospira interrogans serovar Pyrogenes Ab |
Titr |
Ser |
Pt |
SemiQn |
Aggl |
|
ACTIVE |
Leptospira interrogans sv Pyrogenes Ab [Titer] in Serum by Agglutination |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
59364-0 |
|
Aggl |
|
|
Both |
|
|
|
0 |
L inter Pyrogenes Ab Titr Ser Aggl |
|
|
|
N |
|
ABS; Aby; Agg; Agglut; Agglutination; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); ID; Infectious Disease; InfectiousDisease; L inter; L inter Pyrogenes; L interrogans; Leptospirosis; Microbiology; Point in time; Random; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
2.32 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
59365-7 |
Leptospira interrogans serovar Mini Ab |
Titr |
Ser |
Pt |
SemiQn |
Aggl |
|
ACTIVE |
Leptospira interrogans sv Mini Ab [Titer] in Serum by Agglutination |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
59365-7 |
|
Aggl |
|
|
Both |
|
|
|
0 |
L inter Mini Ab Titr Ser Aggl |
|
|
|
N |
|
ABS; Aby; Agg; Agglut; Agglutination; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); ID; Infectious Disease; InfectiousDisease; L inter; L inter Mini; L interrogans; Leptospirosis; Microbiology; Point in time; Random; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
2.32 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
59366-5 |
Leptospira interrogans serovar Sejroe Ab |
Titr |
Ser |
Pt |
SemiQn |
Aggl |
|
ACTIVE |
Leptospira interrogans sv Sejroe Ab [Titer] in Serum by Agglutination |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
59366-5 |
|
Aggl |
|
|
Both |
|
|
|
0 |
L inter Sejroe Ab Titr Ser Aggl |
|
|
|
N |
|
ABS; Aby; Agg; Agglut; Agglutination; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); ID; Infectious Disease; InfectiousDisease; L inter; L inter Sejroe; L interrogans; Leptospirosis; Microbiology; Point in time; Random; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
2.32 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
59367-3 |
Leptospira interrogans serovar Tarassovi Ab |
Titr |
Ser |
Pt |
SemiQn |
Aggl |
|
ACTIVE |
Leptospira interrogans sv Tarassovi Ab [Titer] in Serum by Agglutination |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
59367-3 |
|
Aggl |
|
|
Both |
|
|
|
0 |
L inter Tarassovi Ab Titr Ser Aggl |
|
|
|
N |
|
ABS; Aby; Agg; Agglut; Agglutination; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); ID; Infectious Disease; InfectiousDisease; L inter; L inter Tarassovi; L interrogans; Leptospirosis; Microbiology; Point in time; Random; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
2.32 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
59368-1 |
Leptospira interrogans serovar Bataviae Ab |
Titr |
Ser |
Pt |
SemiQn |
Aggl |
|
ACTIVE |
Leptospira interrogans sv Bataviae Ab [Titer] in Serum by Agglutination |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
59368-1 |
|
Aggl |
|
|
Both |
|
|
|
0 |
L inter Batav Ab Titr Ser Aggl |
|
|
|
N |
|
ABS; Aby; Agg; Agglut; Agglutination; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); ID; Infectious Disease; InfectiousDisease; L inter; L inter Batav; L interrogans; Leptospirosis; Microbiology; Point in time; Random; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
2.32 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
59369-9 |
Leptospira interrogans serovar Hebdomadis Ab |
Titr |
Ser |
Pt |
SemiQn |
Aggl |
|
ACTIVE |
Leptospira interrogans sv Hebdomadis Ab [Titer] in Serum by Agglutination |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
59369-9 |
|
Aggl |
|
|
Both |
|
|
|
0 |
L inter Hebdo Ab Titr Ser Aggl |
|
|
|
N |
|
ABS; Aby; Agg; Agglut; Agglutination; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); ID; Infectious Disease; InfectiousDisease; L inter; L inter Hebdo; L interrogans; Leptospirosis; Microbiology; Point in time; Random; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
2.32 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
5937-8 |
Cocaine |
MCnc |
Urine |
Pt |
Qn |
|
|
DEPRECATED |
Deprecated Cocaine [Mass/volume] in Urine |
|
DEL |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
5937-8 |
|
|
|
|
|
|
|
|
0 |
Deprecated Cocaine Ur-mCnc |
|
|
|
|
|
Addiction; Benzoylmethylecgonine; Coke; Crack; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Ecgonine methyl ester benzoate; Illicit; Level; Mass concentration; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; Snow; UA; UR; Urn |
2.4 |
1.0d |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
59370-7 |
Leptospira interrogans serovar Australis Ab |
Titr |
Ser |
Pt |
SemiQn |
Aggl |
|
ACTIVE |
Leptospira interrogans sv Australis Ab [Titer] in Serum by Agglutination |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
59370-7 |
|
Aggl |
|
|
Both |
|
|
|
0 |
L inter Austral Ab Titr Ser Aggl |
|
|
|
N |
|
ABS; Aby; Agg; Agglut; Agglutination; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); ID; Infectious Disease; InfectiousDisease; L inter; L inter Austral; L interrogans; Leptospirosis; Microbiology; Point in time; Random; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
2.32 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
59371-5 |
Leptospira interrogans serovar Autumnalis Ab |
Titr |
Ser |
Pt |
SemiQn |
Aggl |
|
ACTIVE |
Leptospira interrogans sv Autumnalis Ab [Titer] in Serum by Agglutination |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
59371-5 |
|
Aggl |
|
|
Both |
|
|
|
0 |
L inter Autum Ab Titr Ser Aggl |
|
|
|
N |
|
ABS; Aby; Agg; Agglut; Agglutination; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); ID; Infectious Disease; InfectiousDisease; L inter; L inter Autum; L interrogans; Leptospirosis; Microbiology; Point in time; Random; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
2.32 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
59372-3 |
Leptospira interrogans serovar Ballum Ab |
Titr |
Ser |
Pt |
SemiQn |
Aggl |
|
ACTIVE |
Leptospira interrogans sv Ballum Ab [Titer] in Serum by Agglutination |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
59372-3 |
|
Aggl |
|
|
Both |
|
|
|
0 |
L inter Ballum Ab Titr Ser Aggl |
|
|
|
N |
|
ABS; Aby; Agg; Agglut; Agglutination; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); ID; Infectious Disease; InfectiousDisease; L inter; L inter Ballum; L interrogans; Leptospirosis; Microbiology; Point in time; Random; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
2.32 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
59373-1 |
Special treatments &or programs - none of above - while a resident |
Find |
^Patient |
Pt |
Ord |
MDSv3 |
|
ACTIVE |
Special treatments andor programs - none of above - while a resident [MDSv3] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURVEY.MDS |
|
59373-1 |
|
MDSv3 |
|
|
|
|
|
|
0 |
|
|
|
|
N |
|
Finding; Findings; MDS version 3; Ordinal; Point in time; QL; Qual; Qualitative; Random; Screen; Special Txs/programs - none of above; Survey; SURVEY.MDS; Tx; Txs |
2.44 |
2.32 |
|
|
|
|
|
|
|
|
|
|
|
0 |
59374-9 |
Special treatments &or programs - none of above - while NOT a resident |
Find |
^Patient |
Pt |
Ord |
MDSv3 |
|
ACTIVE |
Special treatments andor programs - none of above - while NOT a resident [MDSv3] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURVEY.MDS |
|
59374-9 |
|
MDSv3 |
|
|
|
|
|
|
0 |
|
|
|
|
N |
|
Finding; Findings; MDS version 3; Ordinal; Point in time; QL; Qual; Qualitative; Random; Screen; Special Txs/programs - none of above; Survey; SURVEY.MDS; Tx; Txs |
2.44 |
2.32 |
|
|
|
|
|
|
|
|
|
|
|
0 |